Relative conformational stability and immunospecificity of PrPSc in the brains of MDR0/0 mice continuously treated with quinacrine compared to untreated controls.

At the endpoint of disease, brain homogenates were exposed to the indicated concentrations of GdnHCl for 1 h, then to 50 µg/mL of PK for 1 h at 37°C. As an additional control, 100 µM quinacrine was added to untreated brain homogenates to mimic the quinacrine content of the treated brain homogenate. The levels of protease-resistant PrPSc were quantitatively measured by ELISA and normalized to 0 M GdnHCl. CDI measurements are the ratio of ELISA signals from PTA-precipitated native and denatured PrPSc as described inMaterials and Methods. Values are mean percentages ± standard error (n = 3). * P